ASCO: Bristol-Myers racks up Opdivo combo data to sell its new biomarker, but will doctors buy it?

Fouad Namouni
Fouad Namouni, Bristol-Myers’ oncology development chief, said “these data will be extremely important in understanding what population of patients is benefitting from I-O combination, whether it’s chemo combination or IO-IO.” (BMS)

CHICAGO—Bristol-Myers Squibb’s new strategy In lung cancer relies on showing its new biomarker can help predict who benefits most from immunotherapy combinations. And Monday at the American Society of Clinical Oncology annual meeting, it rolled out data to support that notion.

Some doctors aren’t convinced, though—and they may just end up reaching for archnemesis Merck’s immuno-oncology star instead.

As part of the Checkmate-227 study, BMS segmented a group of patients whose tumors don’t bear the well-established biomarker PD-L1 to show that combinations featuring its PD-1 med Opdivo—Opdivo and fellow Bristol immunotherapy Yervoy, and Opdivo-plus-chemo—worked better in those with high levels of tumor mutational burden, or TMB.


Veeva 2020 Unified Clinical Operations Survey

We believe you have the knowledge and expertise to make this year's Veeva 2020 Clinical Operations Report even more robust and insightful than the last. Please take a moment to share your opinion in this 10-minute survey. All qualified respondents will be entered to win a $500 Amazon gift card.

The way BMS’ oncology development head, Fouad Namouni, sees it, “these data will be extremely important in understanding what population of patients is benefitting from I-O combination, whether it’s chemo combination or IO-IO,” he said.

For one, they’ll save patients with low TMB and low PD-L1 levels—who “don’t seem to derive benefit from either a chemo combination or an IO combination” that other groups do—some unnecessary exposure to drugs that won’t work, and the side effects that go along with them. “For this reason, I really believe in studying a patients’ biomarker at the time of making treatment decisions,” Namouni said.

RELATED: BMS' Opdivo-Yervoy combo posts big win in first-line lung cancer—but big enough to challenge Merck?

Not everyone’s convinced that TMB should be included in the group of biomarkers that doctors routinely test for in newly diagnosed lung cancer patients. At an ASCO educational panel on Friday, presenting doctors “were all in agreement that TMB testing is not ready for routine clinical practice, recommending against testing all patients for it at this time,” Credit Suisse analyst Vamil Divan wrote in a note to clients.

That discussion picked up right where it left off at April’s American Association for Cancer Research annual meeting, where Bristol worked to build its biomarker case with different Opdivo-Yervoy data in TMB-high patients.

The New Jersey drugmaker, naturally, feels differently about TMB testing; Namouni has said TMB could one day join EGFR, ALK, ROS and others on the list of lung cancer biomarkers used routinely to determine which treatments will work best.

RELATED: ASCO: Merck shows Roche up with big survival numbers in squamous lung cancer

In the meantime, though, Bristol’s chief I-O rival Merck is putting up big numbers across the board in the all-important first-line setting. Its combo of Keytruda and chemo has already shown it could halve the risk of death for patients with non-squamous lung cancer, and over the weekend at ASCO, the Keytruda-chemo pairing showed it could slash that risk by 36% in the squamous population, too.

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.